Всемирная организация здравоохранения (ВОЗ / WHO) · Publications

Hepatitis B control : strategic information and country profiles

23 декабря 2013 г. Всемирная организация здравоохранения

Полный текст размещён на сайте публикующей организации. lawenc.com индексирует метаданные и ведёт на официальный источник.

Полный текст

Hepatitis B Control Strategic Information and Country Profiles

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO web site (www.who.int/about/licensing/copyright_form/en/index.html). ). For WHO Western Pacific Regional Publications, request for permission to reproduce should be addressed to Publications Office, World Health Organization, Regional Office for the Western Pacific, P.O. Box 2932, 1000, Manila, Philippines, fax: +632 521 1036, e-mail: publications@wpro.who.int The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. Cover: AFP

contents 1. Abbreviations IV 2. Context 1 3. Regional Progress: Hepatitis B Control Milestones 2 4. Regional Progress: Chronic Hepatitis B Virus Prevalence 4 5. Regional Progress: Hepatitis B Vaccination Coverage, 1990 – 2011 6 6. Regional Progress: Status of the 2012 Hepatitis B Control Milestone 7 7. Country Profiles American Samoa BruneI Darussalam 8 10 Australia Cambodia China Hong Kong (China) Macao (China) Cook Islands French Polynesia Malaysia Marshall Islands Federated States of Micronesia 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43

Mongolia Nauru New Caledonia New Zealand Northern Mariana Islands Papua New Guinea Republic of Korea

Niue 9 Palau 11 Philippines 12 13 14 15 16 17 18 19 20 21 Samoa Singapore Solomon Islands Tokelau Tonga Tuvalu Vanuatu Viet Nam Wallis and Futuna

Fiji Guam Japan Kiribati Lao People’s Democratic Republic

III

ABBREVIATIONS AusAID BD CDC DHS DTP3 GAVI HB HBV HepB HepB3 HBsAg JRF NZAID SBA WHO UNICEF Australian Agency for International Development Birth Dose Centers for Disease Control and Prevention Demographic and Health Survey Third dose of diphtheria-pertussis-tetanus vaccine Global Alliance for Vaccines and Immunization Hepatitis B Hepatitis B virus Hepatitis B Third dose of hepatitis B vaccine Hepatitis B surface antigen (a marker of hepatitis B infection) Joint reporting form New Zealand Agency for International Development Skilled birth attendant World Health Organization United Nations Children’s Fund

CONTEXT Remarkable progress has been made in controlling hepatitis B infection in the Western Pacific Region. In 2005 the Regional Committee for the Western Pacific made a momentous decision to adopt the world’s first regional hepatitis B control goal. Resolution WPR/RC56.R8 set a goal of less than 1% hepatitis B prevalence among children with a milestone target of less than 2% prevalence by 2012. In 2012 the Region made history by achieving that milestone. The countries and areas of the Western Pacific Region have proven that a well-planned programme including evidence-based policies and careful performance measurement is a formula for success. This document provides an overview of the hepatitis B control programme in the Western Pacific Region, and hepatitis B data profiles for the 36 countries and areas of the Region. The profiles include demographic data, vaccination policies, childbirth delivery types, reported vaccination coverage from 2008–2012, vaccination coverage and seroprevalence survey summaries, and the status of hepatitis B control verification. We are hopeful that this easy-to-ready snapshot of up-to-date data by country will be a useful tool for decision-makers in sustaining and increasing the important gains in hepatitis B control in the Western Pacific Region. The Region has proven that suffering and death due to hepatitis B infection need not continue. Currently nine countries and areas have been verified as having reached the goal of less than 1% hepatitis B prevalence among five-year-old children. Let us continue to work together to ensure that all countries and areas achieve and sustain the goal of less than 1% hepatitis B prevalence among children, and that hepatitis B infection becomes a thing of the past.

Key Milestones Hepatitis B (HB)

HB fact

Country or regional progress

Regional action or recommendations

Global action or recommendation

Partners

100%

Plasma-derived hepatitis B vaccine becomes the first ever cancer preventing vaccine licensed (the recombinant hepatitis B vaccine in use today was licensed in 1986).

The World Health Organization recommends hepatitis B vaccination for all infants.

AusAID, NZAID, WHO and UNICEF implement a project to increase hepatitis B vaccination in Pacific island countries.

GAVI support for hepatitis B vaccine introduction becomes available for GAVI-eligible countries.

All countries and areas in the Region include hepatitis B vaccination as part of their national immunization policies (Japan has targeted vaccination). The Western Pacific Region sets a goal to reduce hepatitis B infection among children to less than 1% with a milestone of less than 2% by 2012.

All countries and areas in the Region adopt hepatitis B birth dose vaccination for all newborn infants with the exception of Japan and New Zealand, which conduct targeted vaccination.

100%

2% The Victorian Infectious Diseases Reference Laboratory (VIDRL) becomes the hepatitis B reference laboratory for the Western Pacific Region. CDC supports WHO Regional Office for the Western Pacific in hepatitis B control. Hong Kong (China) and Malaysia verified as having reached the 1% hepatitis B control goal. Tonga verified as having reached the 2% hepatitis B control milestone. The Western Pacific Region as a whole and at least 30 countries and areas meet the 2% hepatitis B milestone. Australia, China, Mongolia and New Zealand verified as having reached the 1% hepatitis B control goal.

1% The Western Pacific Region holds discussions on setting the target year for the 1% goal. Palau verified as having reached the 1% hepatitis B control goal.

Macao (China) and the Republic of Korea and are the first countries and areas officially verified as having reached the 1% hepatitis B control goal.

WHO recommends hepatitis B birth dose vaccination for all newborn infants.

Regional Progress

Chronic Hepatitis B Virus (HBV) Prevalence in Children

Mongolia

Republic of Korea China Lao People’s Hong Kong (China) Democratic Republic Macao (China) Cambodia Viet Nam Malaysia Commonwealth of Northern Mariana Islands Japan

Chronic HBV prevalence before vaccine >6% prevalence >2% - 6% prevalence <2% prevalence

Philippines

Guam Palau

Federated States of Micronesia Papua New Guinea Nauru Solomon Islands

Marshall Islands Kiribati Tuvalu

Singapore

Brunei Darussalam

Tokelau Samoa American Samoa Niue Cook Islands French Polynesia

Wallis and Futuna Vanuatu Fiji Australia New Caledonia

Tonga

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimination of its fronteriers and boundaries. Dotted lines on maps represents approximate border lines for which there may not yet be full agreement © WHO Regional Office for the Western Pacific 2009. All rights reserved.

New Zealand

Chronic Hepatitis B Virus (HBV) Prevalence in Children

Regional Progress

Mongolia

Republic of Korea China Lao People’s Hong Kong (China) Democratic Republic Macao (China) Cambodia Viet Nam Malaysia Commonwealth of Northern Mariana Islands Japan

Chronic HBV prevalence in 2012 >6% prevalence >2% - 6% prevalence <2% prevalence

Philippines

Guam Palau

Federated States of Micronesia Papua New Guinea Nauru Solomon Islands

Marshall Islands Kiribati Tuvalu

Singapore

Brunei Darussalam

Tokelau Samoa American Samoa Niue Cook Islands French Polynesia

Wallis and Futuna Vanuatu Fiji Australia New Caledonia

Tonga

New Zealand

Regional Progress

Hepatitis B Vaccination Coverage, 1990–2011

% Vaccination coverage

Regional Progress

Status of the 2012 Hepatitis B Control Milestone*

Mongolia

Republic of Korea China Japan

Verified to reach the milestone Likely to have reached the regional milestone Lack prevalence or immunization evidence suggesting milestone has been met

Lao People’s Democratic Republic Cambodia

Hong Kong (China) Macao (China) Philippines Viet Nam Malaysia

Commonwealth of Northern Mariana Islands

*Milestone: <2% childhood hepatitis B infection prevalance

Guam Palau

Federated States of Micronesia Papua New Guinea Nauru Solomon Islands

Marshall Islands Kiribati Tuvalu

Singapore Brunei Darussalam

Tokelau Samoa American Samoa Niue Cook Islands French Polynesia

Wallis and Futuna Vanuatu Fiji Australia New Caledonia

Tonga

New Zealand

American Samoa Neonatal deliveries 1.0% 99.0% Health facility Home with SBA Home with no SBA Unknown

Demographics Total population (2012) Births (2012) Surviving infants (2012) Urban population (2012) 70 680 1375 1359 93%

Hepatitis B vaccine HepB3 introduced nationwide HepB birth dose introduced Current schedule HepB3 type 1986–1987 not reported 0, 1 month, 12 months Monovalent

Reported hepatitis B vaccination coverage 100 Vaccination coverage (%) (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year 1990 National 1995 National 1996 National Ages enrolled 3–4 years 7–8 years 7–8 years Sample HepB BD size % 95 not reported 432 75% 435 not reported HepB3 DTP3 % % 82% not reported 91% not reported 87% not reported Reference/Notes Mahoney Pac Hth Dialog 1996 Bialek ISVHLD P351 2006 Mahoney Pac Hth Dialog 1996

Hepatitis B serological surveys Survey Location year 1991 T utuila 1995 Nationwide 2011 Nationwide Ages enrolled 3–4 years 7–8 years 6 years Sampling base Community based Community based School based Sample size 93 432 562 HBsAG prevalence Reference/Notes (95% CI) 2.2% Mahoney JID 2009 0.5% Bialek ISVHLD P351 2006 0.20% PRELIMINARY DATA

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus, and Pertussis Vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: UN, UNICEF and WHO HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.

Demographics Total population (2012) Births (2012) Surviving infants (2012) Urban population (2012) 22 918 688 310 837 305 841 89%

Hepatitis B vaccine HepB3 introduced nationwide 2000 HepB birth dose introduced 2000 Current schedule 0, 2 months, 4 months, 6 months HepB3 type DTP-Hib-HepB-IPV

Australia

Neonatal deliveries 0.90% Vaccination coverage (%) 99.10% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year 2007 National Ages Sample HepB BD enrolled size % 12 months 280874 not reported HepB3 % 94% DTP3 % 92% Reference/Notes From National Health Insurance covering 99% of population

Hepatitis B serological surveys Survey Location year 2002 Nationwide Ages enrolled 1–9 years Sampling base Hospital based Sample size 249 HBsAG prevalence Reference/Notes (95% CI) 0.4% (0.0% – 2.2%) Gidding Vaccine 2007

WHO verification Status of verifying prevalence targets Verification started: June 2012 Decision: <1% in children Decision date: December 2012

Brunei Darussalam Neonatal deliveries 0.10% 0.10% 99.80% Health facility Home with SBA Home with no SBA Unknown

Demographics Total population (2012) Births (2012) Surviving infants (2012) Urban population (2012) 412 892 7607 7597 76%

Hepatitis B vaccine HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 2 months, 4 months, 6 months HepB3 type DTP-Hib-HepB-IPV

Reported hepatitis B vaccination coverage 100 Vaccination coverage (%) (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year Ages Sample enrolled size HepB BD % HepB3 % DTP3 % Reference/Notes

Hepatitis B serological surveys Survey Location year 2011 National Ages enrolled 8–9 years Sampling base School based Sample size 4513 HBsAG prevalence Reference/Notes (95% CI) not reported MoH 2011 prelim data

WHO verification Status of verifying prevalence targets Verification started: December 2012 Decision: 1% Decision date: June 2013

Demographics Total population (2012) Births (2012) Surviving infants (2012) Urban population (2012) 14 478 320 315 909 303 244 20%

Hepatitis B vaccine HepB3 introduced nationwide 2005 HepB birth dose introduced 2005 Current schedule 0, 6 weeks, 10 weeks,14 weeks HepB3 type DTP-Hib-HepB

Cambodia

Neonatal deliveries 54.0% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100

Districts by coverage categories* 100 (%) Districts 2012 80 60 40 20 0 <50% 50%–79% HepB3

29.0%

Vaccination coverage (%)

80 60 40 20 0 2008 2009 Timely HepB BD

17.0%

2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year 2005 National 2010 National Ages enrolled 12–24 months 12–24 months Sample HepB BD HepB3 DTP3 size % % % 1517 not reported not reported 78% 1614 73% 84% not reported Reference/Notes DHS Survey DHS Survey: birth dose by 12M

Hepatitis B serological surveys Survey Location year 2001 Kg Chhnang 2006 Nationwide 2011 Urban, Rural, Remote Ages enrolled 9–17 months 5 years 4–5 years Sampling base Hospital based Community based Community based Sample size 900 1558 2429 HBsAG prevalence Reference/Notes (95% CI) 2.7% Report MoH/PATH/AIHI 3.5% (2.4% – 4.8%) Soeung AMTH 2009 0.3%, 1.4%, 3.4% PRELIMINARY DATA

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

China

Demographics Total population (2012) Births (2012) Surviving infants (2012) Urban population (2012) 1 353 600 687 16 209 546 16 068 111 50%

Hepatitis B vaccine HepB3 introduced nationwide HepB birth dose introduced Current schedule HepB3 type 1992 1992 0, 1 months, 6 months Monovalent

Neonatal deliveries 3.70% Vaccination coverage (%) 96.30% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year 2006 National Ages Sample enrolled size 1 year 3636 HepB BD % 93% HepB3 DTP3 % % 83% not reported Reference/Notes Liang JID 2009; 2005 birth cohort

Hepatitis B serological surveys Survey Location year 2006 Nationwide 2006 Nationwide 2006 Nationwide Ages enrolled 1–4 years 5 years 6 years Sampling base Community based Community based Community based Sample size 16376 2215 2356 HBsAG prevalence Reference/Notes (95% CI) 1.0% (0.8% – 1.2%) Liang Vaccine 2009 1.1% (0.4% – 1.8%) Liang JID 2009 0.9% (0.4% – 1.5%) Liang JID 2009

WHO verification Status of verifying prevalence targets Verification started: February 2012 Decision: <1% in children Decision date: June 2012

Demographics Total population (2012) Births (2012) Surviving infants (2012) Urban population (2012) 7 196 450 63 272 61 843 95%

Hepatitis B vaccine HepB3 introduced nationwide HepB birth dose introduced Current schedule HepB3 type 1988 1988 0, 1 months, 6 months Monovalent

HONG KONG (CHINA) Districts by coverage categories* 100 (%) Districts 2012 80 60 40 20 0 <50% 50%–79% HepB3

Neonatal deliveries 100.0% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 Vaccination coverage (%) 80 60 40 20 0 2008 2009 Timely HepB BD

2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year 2009 National Ages Sample HepB BD enrolled size % 2–5 years 6248 not reported HepB3 % ≥99.5% DTP3 % >99.8% Reference/Notes MoH HOK 2011

Hepatitis B serological surveys Survey Location year 2006 Nationwide 2009 Nationwide Ages enrolled 1–4 years 12–15 years Sampling base Laboratory based School based Sample size 196 1913 HBsAG prevalence Reference/Notes (95% CI) 1% MoH HOK 2011 0.8% (0.4% – 1.2%) MoH HOK 2011

WHO verification Status of verifying prevalence targets Verification started: February 2011 Decision: <1% in children Decision date: July 2011

MACAO (CHINA)

Demographics Total population (2012) Births (2012) Surviving infants (2012) Urban population (2012) 567 441 5714 5465 100%

Hepatitis B vaccine HepB3 introduced nationwide HepB birth dose introduced Current schedule HepB3 type 1984 1989 0, 1 months, 6 months Monovalent

Neonatal deliveries 100.0% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 Vaccination coverage (%) (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year Ages Sample enrolled size HepB BD % HepB3 % DTP3 % Reference/Notes

Hepatitis B serological surveys Survey Location year 2003 Nationwide Ages enrolled 6–9 years Sampling base School based Sample size 437 HBsAG prevalence Reference/Notes (95% CI) 0% (0% – 0.7%) MoH MAC 2008

WHO verification Status of verifying prevalence targets Verification started: April 2008 Decision: <1% in children Decision date: August 2008

Demographics Total population (2012) Births (2012) Surviving infants (2012) Urban population (2012) 20 528 292 290 75%

Hepatitis B vaccine HepB3 introduced nationwide 1989 HepB birth dose introduced n.a. Current schedule 0, 6 weeks, 3 months, 5 months HepB3 type DTP-Hib-HepB

COOK ISLANDS

Neonatal deliveries 0.40% Vaccination coverage (%) 99.60% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year Ages Sample enrolled size HepB BD % HepB3 % DTP3 % Reference/Notes

Hepatitis B serological surveys Survey Location year 2012 7 of 11 islands Ages enrolled 6 years Sampling base School based Sample size 265 HBsAG prevalence Reference/Notes (95% CI) 0% PRELIMINARY DATA

WHO verification Status of verifying prevalence targets Verification started: October 2011 Decision: n.a. Decision date: n.a.

FIJI

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 875 822 18 201 18 080 52%

Hepatitis B vaccine HepB3 introduced nationwide 1989 HepB birth dose introduced 1989 Current schedule 0, 6 weeks, 10 weeks,14 weeks HepB3 type DTP-Hib-HepB

Neonatal deliveries 0.20% Vaccination coverage (%) 99.80% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year 2008 not reported Ages Sample enrolled size not reported 439 HepB BD % 86% HepB3 DTP3 % % 99% not reported Reference/Notes Confirm data with country

Hepatitis B serological surveys Survey Location year 1998 Large T owns 2008 Sub-national Ages enrolled 12–24 months 6 months–5 years Sampling base Hospital based Community based Sample size 285 428 HBsAG prevalence Reference/Notes (95% CI) 0.7% Wilson Vaccine 2000 0% WHO:RS/2009/GE/23(JPN)

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 276 731 4562 4543 51%

Hepatitis B vaccine HepB3 introduced nationwide HepB birth dose introduced Current schedule HepB3 type 1992 not reported 0, 1 months, 6 months Monovalent

French Polynesia Districts by coverage categories* 100 (%) Districts 2012 80 60 40 20 0 <50% 50%–79% HepB3

Neonatal deliveries 1.00% Vaccination coverage (%) 99.00% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 80 60 40 20 0 2008 2009 Timely HepB BD

2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year Ages Sample enrolled size HepB BD % HepB3 % DTP3 % Reference/Notes

Hepatitis B serological surveys Survey Location year 1988 Austral Island Ages enrolled 0–11 months Sampling base Community based Sample size 957 HBsAG prevalence Reference/Notes (95% CI) 2.1% B Trans R Soc Trop 1990

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

GUAM

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 184 334 3249 3209 93%

Hepatitis B vaccine HepB3 introduced nationwide 1988–1989 HepB birth dose introduced not reported Current schedule 0, 2 months, 4 months, 6 months, 12 months HepB3 type DTP-Hib-HepB

Neonatal deliveries 12.20% 0.60% Vaccination coverage (%) 87.22% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year Ages Sample enrolled size HepB BD % HepB3 % DTP3 % Reference/Notes

Hepatitis B serological surveys Survey Location year Ages enrolled Sampling base Sample size HBsAG prevalence Reference/Notes (95% CI)

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 126 434 653 1 068 161 1 070 409 67%

Hepatitis B vaccine HepB3 introduced nationwide HepB birth dose introduced Current schedule HepB3 type not reported not reported if HBsAg+ mother Monovalent

JAPAN

Neonatal deliveries 0.18% 0.05% Vaccination coverage (%) 99.77% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year Ages Sample enrolled size HepB BD % HepB3 % DTP3 % Reference/Notes

Hepatitis B serological surveys Survey Location year 1989 Okinawa 1995–1996 Nationwide 1995–2000 Nationwide Ages enrolled 1–4 years 16–19 years 16–19 years Sampling base School based Blood Donors Blood Donors Sample size 1529 107879 582415 HBsAG prevalence Reference/Notes (95% CI) 0.1% Hayashi Int J Epi 1990 0.4% (0.4% – 0.5%) Furusyo AMTM 1998 0.23% (0.22% – 0.24%) Tanaka Intervirol 2004

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

Kiribati

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 102 660 1229 1226 48%

Hepatitis B vaccine HepB3 introduced nationwide 1995 HepB birth dose introduced 1990 Current schedule 0, 6 weeks, 10 weeks,14 weeks HepB3 type DTP-Hib-HepB

Neonatal deliveries 1.75% Vaccination coverage (%) 16.40% 81.85% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year Ages Sample enrolled size HepB BD % HepB3 % DTP3 % Reference/Notes

Hepatitis B serological surveys Survey Location year 1998 Large Towns Ages enrolled 12–24 months Sampling base Hospital based Sample size 156 HBsAG prevalence Reference/Notes (95% CI) 3.8% Wilson Vaccine 2000

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 6 373 934 139 845 135 845 33%

Hepatitis B vaccine HepB3 introduced nationwide 2001 HepB birth dose introduced ~ 2005 Current schedule 0, 6 weeks, 10 weeks,14 weeks HepB3 type DTP-Hib-HepB

Lao People’s Democratic Republic Districts by coverage categories* 100 (%) Districts 2012 80 60 40 20 0 <50% 50%–79% HepB3

Neonatal deliveries 12.80% Vaccination coverage (%) 5.70% Health facility Home with SBA Home with no SBA Unknown 81.50%

Reported hepatitis B vaccination coverage 100 80 60 40 20 0 2008 2009 Timely HepB BD

2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year 2006 National Ages Sample HepB BD HepB3 enrolled size % % 12 months 828 not reported not reported DTP3 % 32% Reference/Notes MICS; 41.3% HepB3 by 23M

Hepatitis B serological surveys Survey Location year 2011 National Ages enrolled 5–9 years Sampling base Community based Sample size 1008 HBsAG prevalence Reference/Notes (95% CI) 1.5% PRELIMINARY DATA

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

MALAYSIA

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 29 321 798 581 991 575 324 72%

Hepatitis B vaccine HepB3 introduced nationwide HepB birth dose introduced Current schedule HepB3 type 1989 1989 0, 1 months, 6 months Monovalent

Neonatal deliveries 0.53% 1.35% Vaccination coverage (%) 98.12% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year Ages Sample enrolled size HepB BD % HepB3 % DTP3 % Reference/Notes

Hepatitis B serological surveys Survey Location year 1997–2007 Nationwide 2009 Nationwide 2009 Nationwide Ages enrolled 6–9 years 9 years 10 years Sampling base School based School based School based Sample size 193717 2938 3265 HBsAG prevalence Reference/Notes (95% CI) 0.4% MoH Malaysia 2011 0.2% (0% – 0.3%) MoH Malaysia 2011 0.4% (0.2% – 0.6%) MoH Malaysia 2011

WHO verification Status of verifying prevalence targets Verification started: March 2011 Decision: <1% in children Decision date: July 2011

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 55 717 1301 1287 72%

Hepatitis B vaccine HepB3 introduced nationwide 1990s HepB birth dose introduced 1998 Current schedule 0, 2 months, 4 months, 6 months HepB3 type DTP-HepB-IPV

MARSHALL ISLANDS Districts by coverage categories* 100 (%) Districts 2012 80 60 40 20 0 <50% 50%–79% HepB3

Neonatal deliveries 2.00% 1.00% Vaccination coverage (%) 97.00% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 80 60 40 20 0 2008 2009 Timely HepB BD

2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year 2007 Majuro, Ebeye Ages Sample enrolled size 5–9 years 331 HepB BD % 49% HepB3 DTP3 % % 93% not reported Reference/Notes Bialek Ped Infect Dis 2010

Hepatitis B serological surveys Survey Location year 2007 Majuro, Ebeye Ages enrolled 5–9 years Sampling base School based Sample size 331 HBsAG prevalence Reference/Notes (95% CI) 1.8% (0.4% – 3.3%) Bialek PID 2010

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

Federated States of Micronesia Neonatal deliveries 80.00% Health facility Home with SBA Home with no SBA Unknown 20.00%

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 112 098 2725 2656 23%

Hepatitis B vaccine HepB3 introduced nationwide HepB birth dose introduced Current schedule HepB3 type not reported not reported 0, 2 months, 6 months Monovalent

Reported hepatitis B vaccination coverage 100 Vaccination coverage (%) (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year 1989 National 1992 Chuuk 1994 Pohnpei Ages enrolled 2 years 2 years 3–4 years Sample HepB BD size % 16391 not reported 544 not reported 364 not reported HepB3 DTP3 % % 84% not reported 40% not reported 82% not reported Reference/Notes Manea PH Reports 1992 Mahoney Pac Hth Dialog 1996 Mahoney Pac Hth Dialog 1996

Hepatitis B serological surveys Survey Location year 2005 Chuuk Ages enrolled 2–6 years Sampling base Hospital based Sample size 362 HBsAG prevalence Reference/Notes (95% CI) 2.5% Bialek PID 2010

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 2 844 081 65 450 63 424 63%

Hepatitis B vaccine HepB3 introduced nationwide 1991 HepB birth dose introduced not reported Current schedule 0, 2 months, 3 months, 4 months HepB3 type DTP-Hib-HepB

MONGOLIA

Neonatal deliveries 0.20% 0.20% Vaccination coverage (%) 99.51% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year 1999 Urban Area 1999 Rural 2004 National Ages enrolled 2 years 2 years 8 years Sample HepB BD size % 127 not reported 148 not reported 1145 65% HepB3 DTP3 % % 94% not reported 76% not reported 60% not reported Reference/Notes Edstam Prev Med 2002 Edstam Prev Med 2002 Davaalkham J Epid 2007

Hepatitis B serological surveys Survey Location year 2004 Nationwide 2009 Nationwide Ages enrolled 7–12 years 4 years Sampling base School based Community based Sample size 1145 5894 HBsAG prevalence Reference/Notes (95% CI) 5.2% Davaalkham PI 2007 0.34% MoH Mongolia 2011

WHO verification Status of verifying prevalence targets Verification started: April 2012 Decision: <1% in children Decision date: July 2012

NAURU

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 10 370 365 361 100%

Hepatitis B vaccine HepB3 introduced nationwide 1983 HepB birth dose introduced not reported Current schedule 0, 6 weeks, 10 weeks,14 weeks HepB3 type DTP-Hib-HepB

Neonatal deliveries 97.40% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 Vaccination coverage (%) (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year Ages Sample enrolled size HepB BD % HepB3 % DTP3 % Reference/Notes

Hepatitis B serological surveys Survey Location year Ages enrolled Sampling base Sample size HBsAG prevalence Reference/Notes (95% CI)

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 258 735 4157 4140 57%

Hepatitis B vaccine HepB3 introduced nationwide HepB birth dose introduced Current schedule HepB3 type 1989 1998 (for HBsAg+ moms) 0, 1 months, 6 months Monovalent

NEW CALEDONIA

Neonatal deliveries 8.03% Vaccination coverage (%) 4.37% 87.60% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year Ages Sample enrolled size HepB BD % HepB3 % DTP3 % Reference/Notes

Hepatitis B serological surveys Survey Location year Ages enrolled Sampling base Sample size HBsAG prevalence Reference/Notes (95% CI)

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

NEW ZEALAND

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 4 461 257 64 499 64 075 86%

Hepatitis B vaccine HepB3 introduced nationwide HepB birth dose introduced Current schedule HepB3 type 1985 not reported 6 weeks, 3 months, 5 months DTP-Hib-HepB-IPV

Neonatal deliveries 4.70% Vaccination coverage (%) 95.30% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year 2005 National Ages Sample enrolled size 12 months 1563 HepB BD % 72% HepB3 % 82% DTP3 % 85% Reference/Notes MoH; 87% HepB3 by 2Y

Hepatitis B serological surveys Survey Location year 2009 North Islands Ages enrolled 6 years Sampling base Community based Sample size 466 HBsAG prevalence Reference/Notes (95% CI) 0.2% (0.0% – 1.2%) Weir R. MoH NEZ 2009

WHO verification Status of verifying prevalence targets Verification started: April 2012 Decision: <1% in children Decision date: September 2012

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 1385 25 25 38%

Hepatitis B vaccine HepB3 introduced nationwide not reported HepB birth dose introduced not reported Current schedule 0, 6 weeks, 3 months, 5 months HepB3 type DTP-Hib-HepB-IPV

Niue

Neonatal deliveries 100.0% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 Vaccination coverage (%) (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year Ages Sample enrolled size HepB BD % HepB3 % DTP3 % Reference/Notes

Hepatitis B serological surveys Survey Location year Ages enrolled Sampling base Sample size HBsAG prevalence Reference/Notes (95% CI)

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

Northern Mariana Islands

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 62 152 1075 1067 91%

Hepatitis B vaccine HepB3 introduced nationwide HepB birth dose introduced Current schedule HepB3 type 1988 1988 0, 6 weeks, 6 months DTP-HepB-IPV

Neonatal deliveries 100.0% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 Vaccination coverage (%) (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year 1995 National 2005 National Ages enrolled 3–4 years 19–35 months Sample HepB BD size % 200 not reported 295 100% HepB3 DTP3 % % 94% not reported 94% not reported Reference/Notes Mahoney Pac Hth Dialog 1996 not reported

Hepatitis B serological surveys Survey Location year 1994 Saipan Ages enrolled 3–4 years Sampling base Health facility Sample size 200 HBsAG prevalence Reference/Notes (95% CI) 0.5% Durand Pac Hlth Dial 1996

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 20 758 269 266 83%

Hepatitis B vaccine HepB3 introduced nationwide 1989 HepB birth dose introduced 1989 Current schedule 0, 6 weeks, 4 months, 6 months HepB3 type DTP-HepB-IPV

PALAU

Neonatal deliveries 100.0% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 Vaccination coverage (%) (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year 2003 National Ages Sample enrolled size 10–11 years 192 HepB BD % 100% HepB3 DTP3 % % 85% not reported Reference/Notes Bialek ISVHLD P351 2006

Hepatitis B serological surveys Survey Location year 2003 Nationwide Ages enrolled 10–11 years Sampling base Community based Sample size 192 HBsAG prevalence Reference/Notes (95% CI) 0% Bialek ISVHLD P351 2006

WHO verification Status of verifying prevalence targets Verification started: January 2013 Decision: <1% in children Decision date: May 2013

Papua New Guinea Neonatal deliveries

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 7 170 112 209 788 200 631 13%

Hepatitis B vaccine HepB3 introduced nationwide 1989 HepB birth dose introduced ~ 2005 Current schedule 0, 1 months, 2 months, 3 months HepB3 type DTP-Hib-HepB

Reported hepatitis B vaccination coverage 100 (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

60.00%

Vaccination Coverage (%)

40.00% Health facility Home with SBA Home with no SBA Unknown

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year Ages Sample enrolled size HepB BD % HepB3 % DTP3 % Reference/Notes

Hepatitis B serological surveys Survey Location year 1989–1990 Port Moresby Ages enrolled 3–5 months Sampling base Hospital based Sample size 31 HBsAG prevalence Reference/Notes (95% CI) 13% Nemba A TPaed. 1993

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 96 471 461 2 373 167 2 312 678 49%

Hepatitis B vaccine HepB3 introduced nationwide 1991 HepB birth dose introduced 2007 Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB

PHILIPPINES

Neonatal deliveries 44.0% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100

Districts by coverage categories* 100 (%) Districts 2012 80 60 40 20 0 <50% 50%–79% HepB3

37.80%

Vaccination coverage (%)

80 60 40 20 0 2008 2009 Timely HepB BD

2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

18.20%

Any HepB BD

Vaccination coverage surveys Survey Location year 2003 National 2008 National Ages enrolled 12–24 months 12–24 months Sample HepB BD size % 1348 not reported 1286 not reported HepB3 % NR 80.3 DTP3 % 79 NR Reference/Notes DHS Survey DHS Survey

Hepatitis B serological surveys Survey Location year Ages enrolled Sampling base Sample size HBsAG prevalence Reference/Notes (95% CI)

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

Republic of Korea Neonatal deliveries 0.10%

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 48 588 326 480 209 477 779 83%

Hepatitis B vaccine HepB3 introduced nationwide HepB birth dose introduced Current schedule HepB3 type 1983 1983 0, 1 month, 6 months Monovalent

Reported hepatitis B vaccination coverage 100 Vaccination Coverage (%) 99.90% Health facility Home with SBA Home with no SBA Unknown (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year 2008 National 2011 National Ages enrolled 0–6 years 0–3 years Sample size 1026 7040 HepB BD % 100% 99% HepB3 % 93% 98% DTP3 % 94.7% 93.4% Reference/Notes CDC Korea; provided during 2012 TAG CDC Korea; provided during 2012 TAG

Hepatitis B serological surveys Survey Location year 2005 Nationwide 2007 Nationwide Ages enrolled 10–14 years 4–6 years Sampling base Community based Hospital based Sample size 594 2920 HBsAG prevalence Reference/Notes (95% CI) 0.2% (0.0% – 0.6%) CDC Korea 2008 0.2% (0.0% – 0.4%) CDC Korea 2008

WHO verification Status of verifying prevalence targets Verification started: January 2008 Decision: <1% in children Decision date: June 2008

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 184 772 4408 4375 20%

Hepatitis B vaccine HepB3 introduced nationwide 1990 HepB birth dose introduced ~ 2005 Current schedule 0, 6 weeks, 10 weeks,14 weeks HepB3 type DTP-Hib-HepB

SAMOA

Neonatal deliveries 81.00% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100

Districts by coverage categories* 100 (%) Districts 2012 80 60 40 20 0 <50% 50%–79% HepB3

19.00%

Vaccination coverage (%)

80 60 40 20 0 2008 2009 Timely HepB BD

2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year 2009 National Ages Sample enrolled size 12–24 months 321 HepB BD HepB3 DTP3 % % % 70% not reported not reported Reference/Notes DHS Survey

Hepatitis B serological surveys Survey Location year Ages enrolled Sampling base Sample size HBsAG prevalence Reference/Notes (95% CI)

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

SINGAPORE

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 5 256 278 48 522 46 946 100%

Hepatitis B vaccine HepB3 introduced nationwide HepB birth dose introduced Current schedule HepB3 type 1985 1987 0, 1 months, 5 months Monovalent

Neonatal deliveries 0.26% Vaccination coverage (%) 99.74% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0

80 60 40 20 0 2010 HepB3

2011

2012

<50%

50%–79% HepB3

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year 2007 National Ages Sample HepB BD enrolled size % 2 years 31778 not reported HepB3 % 94–96% DTP3 % 97% Reference/Notes NR

Hepatitis B serological surveys Survey Location year 1998–1999 National Ages enrolled 0–4 years Sampling base not reported Sample size 229 HBsAG prevalence Reference/Notes (95% CI) 0% Epi News Bull SNG 2000

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 566 481 17 414 16 761 19%

Hepatitis B vaccine HepB3 introduced nationwide 1990 HepB birth dose introduced ~ 2005 Current schedule 0, 6 weeks, 10 weeks,14 weeks HepB3 type DTP-Hib-HepB

SOLOMON ISLANDS Districts by coverage categories* 100 (%) Districts 2012 80 60 40 20 0 <50% 50%–79% HepB3

Neonatal deliveries 14.00% 1.00% Health facility Home with SBA Home with no SBA Unknown Vaccination coverage (%) 85.00%

Reported hepatitis B vaccination coverage 100 80 60 40 20 0 2008 2009 Timely HepB BD

2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year Ages Sample enrolled size HepB BD % HepB3 % DTP3 % Reference/Notes

Hepatitis B serological surveys Survey Location year 1999 Guadalcanal Islands Ages enrolled 0–9 years Sampling base Hospital based Sample size 115 HBsAG prevalence Reference/Notes (95% CI) 13% Furusyo Am J Trop 1999

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

Tokelau

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 1136 18 21 0%

Hepatitis B vaccine HepB3 introduced nationwide not reported HepB birth dose introduced not reported Current schedule 0, 6 weeks, 10 weeks,14 weeks HepB3 type DTP-Hib-HepB

Neonatal deliveries 100.0% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 Vaccination coverage (%) (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year Ages Sample enrolled size HepB BD % HepB3 % DTP3 % Reference/Notes

Hepatitis B serological surveys Survey Location year Ages enrolled Sampling base Sample size HBsAG prevalence Reference/Notes (95% CI)

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 104 891 2731 2724 23%

Hepatitis B vaccine HepB3 introduced nationwide 1989 HepB birth dose introduced not reported Current schedule 0, 6 weeks, 10 weeks,14 weeks HepB3 type DTP-Hib-HepB

TONGA

Neonatal deliveries 0.40% 1.60% Vaccination coverage (%) 98.00% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year 2005 Tongatapu hospital Ages Sample enrolled size 6–59 months 445 HepB BD % 92% HepB3 % 98% DTP3 % 98% Reference/Notes Danielsson Vaccine 2009

Hepatitis B serological surveys Survey Location year 1998 Large T owns 2005 Main Island Ages enrolled 12–24 months 6–59 months Sampling base Hospital based Hospital based Sample size 211 375 HBsAG prevalence Reference/Notes (95% CI) 3.8% Wilson Vaccine 2000 0.8% (0.2% – 2.5%) Danielsson Vaccine 2009

WHO verification Status of verifying prevalence targets Verification started: May 2011 Decision: <2% in children Decision date: January 2012

TUVALU

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 9867 277 277 50%

Hepatitis B vaccine HepB3 introduced nationwide not reported HepB birth dose introduced not reported Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB

Neonatal deliveries 100.0% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 Vaccination coverage (%) (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year Ages Sample enrolled size HepB BD % HepB3 % DTP3 % Reference/Notes

Hepatitis B serological surveys Survey Location year 1976 Fanafuti Ages enrolled 10–19 years Sampling base Community based Sample size 181 HBsAG prevalence Reference/Notes (95% CI) 11% Gust JID 1979

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 251 674 7274 7019 26%

Hepatitis B vaccine HepB3 introduced nationwide 1989–1990 HepB birth dose introduced 1989–1990 Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB

Vanuatu

Neonatal deliveries 80.0% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100

Districts by coverage categories* 100 (%) Districts 2012 80 60 40 20 0 <50% 50%–79% HepB3

20.0%

Vaccination coverage (%)

80 60 40 20 0 2008 2009 Timely HepB BD

2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year 2007 National Ages Sample HepB BD enrolled size % 13 months 359 not reported HepB3 % 59% DTP3 % 58% Reference/Notes MICS; 55.3% HepB3 by 23M

Hepatitis B serological surveys Survey Location year 1998 Large T owns 1988 Emao or Nguna Ages enrolled 12–24 months 12–18 months Sampling base Hospital based Community based Sample size 132 112 HBsAG prevalence Reference/Notes (95% CI) 3.0% Wilson Vaccine 2000 17% Maher Med J Aust 1991

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

VIET NAM

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 89 730 274 1 444 753 1 433 094 30%

Hepatitis B vaccine HepB3 introduced nationwide 1997 HepB birth dose introduced 2005 Current schedule 0, 2 months, 3 months, 4 months HepB3 type DTP-Hib-HepB

Neonatal deliveries 5.60% Vaccination coverage (%) 94.40% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year 2002 National 2006 National Ages enrolled 12–24 months 12 months Sample HepB BD HepB3 size % % 457 not reported not reported 555 not reported 32% DTP3 % 72% 76% Reference/Notes DHS Survey MICS; 33.9% HepB3 by 23M

Hepatitis B serological surveys Survey Location year 1998 Thanh Hoa 2011 National 2011 National Ages enrolled 9–18 months 3–4 years 5–7 years Sampling base Community based Community based Community based Sample size 536 3426 1738 HBsAG prevalence Reference/Notes (95% CI) 12.5% Hipgrave AJTMH 2003 1.6% PRELIMINARY DATA 2.10% PRELIMINARY DATA

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

Demographics Total Population (2012) Births (2012) Surviving infants (2012) Urban Population (2012) 13 348 182 177 0%

Hepatitis B vaccine HepB3 introduced nationwide not reported HepB birth dose introduced not reported Current schedule 0, 2 months, 3 months, 4 months, 16 months HepB3 type DTP-HepB-IPV

Wallis and Futuna

Neonatal deliveries 100.0% Health facility Home with SBA Home with no SBA Unknown

Reported hepatitis B vaccination coverage 100 Vaccination coverage (%) (%) Districts 2012 2008 2009 Timely HepB BD

Districts by coverage categories* 100 80 60 40 20 0 <50% 50%–79% HepB3

80 60 40 20 0 2010 HepB3

2011

2012

80%–89% 90%–94% Timely HepB BD

>94%

Any HepB BD

Vaccination coverage surveys Survey Location year 2011 National Ages Sample HepB BD enrolled size % 7–12 years 442 not reported HepB3 DTP3 % % 94% not reported Reference/Notes Data from national serosurvey

Hepatitis B serological surveys Survey Location year 2012 National Ages enrolled 7–12 years Sampling base School-based Sample size 469 HBsAG prevalence Reference/Notes (95% CI) 0.4% (0% – 1.0%) PRELIMINARY DATA

WHO verification Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a.

Expanded Programme on Immunization Regional Office for the Western Pacific World Health Organization P.O. Box 2932, 1000 Manila, Philippines Tel. no. (+63 2) 5288001 Fax no. (+63 2) 5211036, 5260279 epi@wpro.who.int

Основные сведения

Организация Всемирная организация здравоохранения (ВОЗ / WHO)

Тип документа Publications

Дата принятия 23 декабря 2013 г.

Источник Всемирная организация здравоохранения